GENE 0.8 (-27.93%)
SE0000661613Medical Diagnostics & ResearchDiagnostics & Research

Genetic Technologies (GENE) Competitor Comparison

We are evaluating the key criteria listed to compare Genetic Technologies (GENE) against its competitors in the Diagnostics & Research industry.

Linearity 3 years - GENE ranking 0 / 58

These are the competitors of Genetic Technologies in the industry Diagnostics & Research ranked by linearity 3 years
1. DexCom DXCM
128.86
2. Natera NTRA
87.81
3. Danaher DHR
84.76
4. Thermo Fisher Scientific TMO
38.48
5. Ortho Clinical Diagnostics Holdings OCDX
33.4
6. Mettler-Toledo MTD
31.16
7. Quest Diagnostics DGX
28.13
8. IQVIA Holdings IQV
20.15
9. Qiagen QGEN
19.35
10. Agilent Technologies A
17.46
11. PerkinElmer PKI
16.14
12. Laboratory Corp of America Holdings LH
14.87
13. Myriad Genetics MYGN
11.42
14. Syneos Health SYNH
10.68
15. Waters WAT
10.38
16. Heska HSKA
7.67
17. Anixa Biosciences ANIX
7.27
18. IDEXX Laboratories IDXX
6.7
19. Olink Holding OLK
6.67
20. Sotera Health SHC
4.31
21. Global Cord Blood CO
4.22
22. Charles River Laboratories CRL
4.06
23. National Research NRC
4
24. Psychemedics PMD
3.41
25. Enzo Biochem ENZ
3.28
26. Icon ICLR
3.23
27. Sera Prognostics SERA
3.14
28. Exact Sciences EXAS
2.99
29. Neogen NEOG
2.71
30. Fulgent Genetics FLGT
2.67
31. Twist Bioscience TWST
2.51
32. Bioventus BVS
2.47
33. Illumina ILMN
2.34
34. NeoGenomics NEO
2.31
35. Co-Diagnostics CODX
2.19
36. MDxHealth MDXH
2.19
37. Inotiv NOTV
2.16
38. Guardant Health GH
2.14
39. MaxCyte MXCT
1.98
40. bioAffinity Technologies BIAF
1.91
41. Pacific Biosciences of California PACB
1.89
42. Exagen XGN
1.88
43. Prenetics Global PRE
1.88
44. Interpace Biosciences IDXG
1.83
45. Organovo Holdings ONVO
1.79
46. DarioHealth DRIO
1.79
47. CareDx CDNA
1.75
48. Trinity Biotech TRIB
1.73
49. Precipio PRPO
1.72
50. Neuronetics STIM
1.64
51. Personalis PSNL
1.57
52. Biodesix BDSX
1.56
53. SeqLL SQL
1.48
54. Aspira Womens Health AWH
1.38
55. RadNet RDNT
1.06
56. Medpace Holdings MEDP
0.8
57. Meridian Bioscience VIVO
0.73
58. Lantheus Holdings LNTH
0.44

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.